HUTCHMED (China) Past Earnings Performance
Past criteria checks 3/6
HUTCHMED (China)'s earnings have been declining at an average annual rate of -3.8%, while the Pharmaceuticals industry saw earnings growing at 0.5% annually. Revenues have been growing at an average rate of 31.7% per year. HUTCHMED (China)'s return on equity is 13.6%, and it has net margins of 12%.
Key information
-3.8%
Earnings growth rate
0.7%
EPS growth rate
Pharmaceuticals Industry Growth | 14.1% |
Revenue growth rate | 31.7% |
Return on equity | 13.6% |
Net Margin | 12.0% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
We Think HUTCHMED (China) (LON:HCM) Can Manage Its Debt With Ease
Apr 04HUTCHMED (China) Limited's (LON:HCM) P/S Is Still On The Mark Following 31% Share Price Bounce
Mar 14The HUTCHMED (China) Limited (LON:HCM) Analysts Have Been Trimming Their Sales Forecasts
Mar 01Market Cool On HUTCHMED (China) Limited's (LON:HCM) Revenues
Dec 18HUTCHMED (China) (LON:HCM) Is Using Debt Safely
Nov 23Does HUTCHMED (China) (LON:HCM) Have A Healthy Balance Sheet?
Aug 24Is HUTCHMED (China) (LON:HCM) A Risky Investment?
May 10With HUTCHMED (China) Limited (LON:HCM) It Looks Like You'll Get What You Pay For
Apr 19Revenue & Expenses BreakdownBeta
How HUTCHMED (China) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 838 | 101 | 133 | 0 |
30 Sep 23 | 798 | 36 | 129 | 0 |
30 Jun 23 | 757 | -29 | 125 | 0 |
31 Mar 23 | 592 | -195 | 130 | 0 |
31 Dec 22 | 426 | -361 | 136 | 0 |
30 Sep 22 | 414 | -308 | 144 | 0 |
30 Jun 22 | 401 | -255 | 152 | 0 |
31 Mar 22 | 376 | -235 | 144 | 0 |
31 Dec 21 | 356 | -195 | 127 | 0 |
30 Sep 21 | 317 | -187 | 108 | 0 |
30 Jun 21 | 279 | -178 | 89 | 0 |
31 Mar 21 | 258 | -151 | 72 | 0 |
31 Dec 20 | 228 | -126 | 61 | 0 |
30 Sep 20 | 221 | -117 | 55 | 0 |
30 Jun 20 | 209 | -110 | 54 | 0 |
31 Mar 20 | 204 | -102 | 51 | 0 |
31 Dec 19 | 205 | -106 | 53 | 0 |
30 Sep 19 | 205 | -93 | 55 | 0 |
30 Jun 19 | 214 | -87 | 51 | 0 |
31 Mar 19 | 214 | -83 | 51 | 0 |
31 Dec 18 | 214 | -75 | 49 | 0 |
30 Sep 18 | 218 | -72 | 46 | 0 |
30 Jun 18 | 217 | -61 | 46 | 0 |
31 Mar 18 | 230 | -39 | 44 | 0 |
31 Dec 17 | 241 | -27 | 43 | 0 |
30 Sep 17 | 240 | -7 | 43 | 0 |
30 Jun 17 | 238 | 13 | 42 | 0 |
31 Mar 17 | 227 | 12 | 41 | 0 |
31 Dec 16 | 216 | 12 | 40 | 0 |
30 Sep 16 | 200 | 38 | 51 | 0 |
30 Jun 16 | 200 | -8 | 37 | 0 |
31 Mar 16 | 189 | -22 | 34 | 0 |
31 Dec 15 | 178 | -35 | 30 | 0 |
30 Sep 15 | 168 | -80 | 12 | 0 |
30 Jun 15 | 139 | -66 | 15 | 0 |
31 Mar 15 | 113 | -50 | 16 | 0 |
31 Dec 14 | 87 | -35 | 17 | 0 |
30 Sep 14 | 72 | -20 | 18 | 0 |
30 Jun 14 | 59 | 7 | 24 | 0 |
31 Mar 14 | 52 | 8 | 24 | 0 |
31 Dec 13 | 37 | 26 | 16 | 0 |
30 Sep 13 | 38 | 10 | 26 | 0 |
30 Jun 13 | 30 | 13 | 28 | 0 |
Quality Earnings: HCM has high quality earnings.
Growing Profit Margin: HCM became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HCM has become profitable over the past 5 years, growing earnings by -3.8% per year.
Accelerating Growth: HCM has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: HCM has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: HCM's Return on Equity (13.6%) is considered low.